Case Study: GSK to acquire Novartis’s consumer healthcare stake for $13bn
Posted on28 Mar 2018
Tagsacquisition in pharma, brand acquisition, GSK, novartis, OTC drugs, otc monograph, pharma acquisition
Comments0
Swiss drugmaker, Novartis agreed to sell GSK its stake in their consumer health joint venture for $13bn. GlaxoSmithKline will be getting the... Read More
US FDA approves Novartis’ Tasigna to treat children with rare form of leukemia
Posted on25 Mar 2018
Comments0
Novartis announced that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and... Read More
AstraZeneca receives EU approval for Lokelma to treat adults with hyperkalaemia
AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults... Read More
What is the significance of Phase 2b Clinical Trial?
In clinical trial, Phase 1 and 2 trials establish proof-of-concept, and phase 3 trials establish the efficacy and safety of the treatment... Read More
Brand Positioning: GSK Consumer Healthcare Ltd launches Horlicks Protein+
Posted on19 Mar 2018
Comments0
GSK Consumer Healthcare Ltd, the maker of Horlicks, is making another attempt to diversify. The company is set to launch Horlicks Protein+,... Read More
Case Study: Lundbeck acquires Prexton Therapeutics
Posted on19 Mar 2018
Comments0
Lundbeck has agreed to acquire Prexton Therapeutics for up to €905 million ($1.1 billion), in a deal that adds a Phase II... Read More
DRL’s API plant in Medak and Biocon’s Malaysian Plant got USFDA 483 observations
Posted on19 Mar 2018
Tags483, 483 OBSERVATION, 483 observations, fda 483 observation, form 483 observation, usfda 483 form
Comments0
Dr Reddy’s Laboratories received the US Food and Drug Administration has issued a Form 483 with four observations after inspecting its active... Read More